Brainsway(US:BWAY) GlobeNewswire News Room·2024-09-10 12:00Core Viewpoint - BrainsWay Ltd. has received approval from the Israel Ministry of Defense for the reimbursement of its Deep Transcranial Magnetic Stimulation (Deep TMS™) therapy for patients with post-traumatic stress disorder (PTSD) in Israeli public hospitals, marking a significant step in addressing the mental health crisis exacerbated by recent conflicts in the region [1][3]. Company Overview - BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep TMS™ technology to improve health outcomes [5]. - The company has obtained three FDA-cleared indications for its TMS technology, which include major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5]. - Founded in 2003, BrainsWay operates from Burlington, MA, and Jerusalem, Israel, and is focused on expanding global awareness and access to Deep TMS [5]. Industry Context - The prevalence of PTSD in Israel is a growing concern, particularly following the October 7th Hamas-led attacks, with estimates suggesting that over 5% of the population may develop PTSD [4]. - A recent study involving 99 military veterans treated with Deep TMS showed significant reductions in PTSD symptoms (44.1%), depression (43.5%), and suicidal ideation (54%) after six months [4]. Future Directions - The company aims to expand the reimbursement program for PTSD treatment to include more medical centers and private clinics in Israel [2]. - Although Deep TMS is not yet FDA-cleared for PTSD treatment, the reimbursement program is expected to facilitate the collection of additional efficacy and safety data to support future applications [6].